Clinical safety of a low-modification hyaluronic acid filler (MoD 2%) for facial rejuvenation

低改性透明质酸填充剂(MoD 2%)用于面部年轻化的临床安全性

阅读:1

Abstract

BACKGROUND: The degree of modification (MoD) of hyaluronic acid (HA) fillers reflects the extent of chemical cross-linking of native HA chains. Lower MoD values correspond to reduced cross-linker content and potentially more physiological behavior, but may also shorten filler longevity. Recent work on HA filler chemistry suggests that cross-linking intensity and impurity load contribute to delayed inflammatory reactions, nodules, and granulomas. OBJECTIVES: To evaluate the long-term safety and clinical performance of a low-MoD (2%) HA filler (Volonic Light, Volonic Co., Ltd., Korea) over 24 months, focusing on the incidence of granulomas, nodules, and delayed inflammatory reactions, as well as durability and patient-reported satisfaction. METHODS: In this prospective, single-center, single-arm cohort study, n = 60 adults underwent facial rejuvenation with a monophasic, lidocaine-containing HA filler with MoD 2% (Volonic Light; Volonic Co., Ltd., Korea). Injections targeted fine lines and contours in the mid- and superficial dermis. RESULTS: Across 60 patients and 24 months of observation, no clinically apparent granulomas, delayed-onset nodules, or persistent inflammatory reactions were observed at any time point. Early post-injection events included transient edema (24/60, 40.0%) and ecchymosis (9/60, 15.0%), which resolved spontaneously within 7-10 days. CONCLUSIONS: In this single-center, single-arm cohort (n = 60), a low-MoD (2%) HA filler was not associated with clinically apparent granulomas or delayed-onset nodules during 24 months of follow-up, and showed a predictable, near-complete clinical resolution of effect by 2 years.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。